Mineralys Therapeutics (MLYS) Income Statement: Revenue & Earnings

Mineralys Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Mineralys Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.04	0.00	0.00	0.00	0.00
Gross Profit	-0.04	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	168.58	70.36	26.25	16.31	2.41
Selling, General & Administrative	23.82	14.30	5.23	2.42	0.53
Operating Expenses	192.40	84.66	31.48	18.73	2.94
Operating Income	-192.40	-84.66	-31.48	-18.73	-2.94
Other Income/Expense
Interest Income	14.59	12.76	1.68	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.03	-0.12
Other Income/Expense	0.01	0.00	0.00	-0.66	-0.37
Income
Income Before Tax	-177.81	-71.90	-29.80	-19.41	-3.43
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-177.81	-71.90	-29.80	-19.41	-3.43
Net Income - Continuous Operations	-177.81	-71.90	-29.80	-19.41	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-192.36	-71.90	-31.48	-19.38	0.00
EBIT	-192.40	-84.66	-31.48	-19.38	-2.94
Depreciation & Amortization	0.04	0.00	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-4.00	-2.00	-6.00	-4.00	-1.00
Diluted EPS	-4.00	-2.00	-6.00	-4.00	-1.00
Basic Shares Outstanding	48.54	36.19	5.17	5.15	4.63
Diluted Shares Outstanding	48.54	36.19	5.17	5.15	4.63